Please login to the form below

Not currently logged in
Email:
Password:

President of Lilly Oncology resigns

John H Johnson, president of Lilly Oncology has resigned effective January 28, citing personal considerations

John H Johnson, senior vice president and president of Lilly Oncology has resigned effective January 28, citing personal considerations.

Johnson was previously CEO of ImClone Systems, and joined Lilly when it acquired the cancer-focused biotech company in 2008. Lilly has not yet named a successor to lead its oncology unit, but said it will do so in the coming weeks.

Lilly chairman, president and CEO John Lechleiter said in a statement that Johnson "has guided the Lilly Oncology pipeline to an all-time high – one of the largest clinical-stage pipelines of potential cancer medicines in the industry."

Lilly Oncology's portfolio of marketed drugs includes the non-small cell lung cancer treatment Alimta and the ovarian cancer therapy Gemzar. The company has also declared a commitment to developing personalised cancer medications.

Johnson became CEO of ImClone in 2007, leaving his post as company group chairman of Johnson & Johnson's worldwide biopharmaceuticals unit, where he had responsibility for that company's biotechnology, immunology and oncology commercial businesses.

The $6.5bn acquisition of ImClone was the largest in Lilly's history. The deal was driven in large part by Lilly's desire to add ImClone's targeted cancer therapy Erbitux (cetuximab) to its portfolio.

25th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics